

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANXI CENTRAL PHARMACEUTICAL INTERNATIONAL LIMITED

正中藥業國際有限公司*

(incorporated in Bermuda with limited liability)

ANNOUNCEMENT

At the annual general meeting held on 22 November, 2002, the ordinary resolution relating to the termination of the existing share option scheme and adoption of a new share option scheme was duly approved by the shareholders of the Company.

Reference is made to the circular of Shanxi Central Pharmaceutical International Limited (the “**Company**”) dated 30 October, 2002 (the “**Circular**”) in relation to the termination of the existing share option scheme and adoption of a new share option scheme. Terms used in this announcement shall have the same meaning as defined in the Circular unless provided otherwise.

The Directors of the Company are pleased to announce that at the annual general meeting held on 22 November, 2002, the ordinary resolution relating to the termination of the existing share option scheme and adoption of a new share option scheme was duly approved by the shareholders of the Company. The New Scheme will come into effect upon the Stock Exchange granting the approval of the listing of and permission to deal in any new Shares representing 10% of the total issued share capital of the Company as at the date of annual general meeting to be issued by the Company pursuant to the exercise of options granted in accordance with the terms and conditions of the New Scheme.

By Order of the Board
Shanxi Central Pharmaceutical International Limited
David Y.M. Shi
Deputy Chairman and Managing Director

Hong Kong, 22 November, 2002

* *for identification only*

“Please also refer to the published version of this announcement in The Standard”.